Goldman Sachs
IKT icon

Goldman Sachs’s Inhibikase Therapeutics IKT Stock Holding History

Goldman Sachs’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$252K Buy
149,857
+64,590
+76% +$115K ﹤0.01% 5981
2025
Q4 		$175K Buy
85,267
+74,532
+694% +$119K ﹤0.01% 6074
2025
Q3 		$17.4K Buy
+10,735
New +$18.6K ﹤0.01% 6239
2025
Q2 		– Sell
-166,025
Closed -$364K – 6244
2025
Q1 		$364K Buy
166,025
+122,073
+278% +$307K ﹤0.01% 5372
2024
Q4 		$143K Buy
+43,952
New +$110K ﹤0.01% 5701
2021
Q4 		– Sell
-4,649
Closed -$53K – 6564
2021
Q3 		$53K Buy
+4,649
New +$62.9K ﹤0.01% 6034

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs's IKT Position: Q1 2026 in Review

Goldman Sachs increased its Inhibikase Therapeutics (IKT) stake by 76% in Q1 2026, buying an estimated $115K and bringing the position to 149,857 shares worth $252K. The position accounts for ﹤0.01% of the portfolio, ranked #5981.

Goldman Sachs first reported a position in IKT in Q3 2021 and has held it in 6 quarters since. The position peaked at $364K in Q1 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Goldman Sachs held 149,857 shares of Inhibikase Therapeutics worth $252K as of Q1 2026.
  • Goldman Sachs bought 64,590 Inhibikase Therapeutics shares in Q1 2026, an estimated $115K.
  • Inhibikase Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5981 holding.
  • Goldman Sachs first reported a position in Inhibikase Therapeutics in Q3 2021 and has held it in 6 quarters since.
  • Goldman Sachs's Inhibikase Therapeutics position peaked at $364K in Q1 2025.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.